In Competition Law and Policy Debate, Raphaël De Coninck highlights the European Commission’s recent interest in assessing the impact of pharmaceutical mergers on innovation. The article discusses the Commission’s approach and argues in favor of developing a consistent framework for assessing the impact of mergers on innovations. To read more, click the link below.
IP Literature Watch: May 2025
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law...